Pharmamarketeer

Gilead seals $3bn deal, hoping for off-the-shelf CAR-T

The expense and laborious process involved in bringing CAR-T therapies to patients was used a key reason for the high cost of the treatments; now, the next step in the field is to find a way to speed up this process, whoever gets there first will have a big advantage.

 

Reageer

Medhc-fases-banner
Advertentie(s)